Clinical trials: Oligodendroglioma, Anaplastic
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumor, Anaplastic Astrocytoma
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
RATIONALE: Ritonavir and lopinavir may stop the growth of gliomas by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01095094
- Testing
- ritonavir, lopinavir
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy.
- Conditions
- Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma
- Trial name
- NCT00679354
- Testing
- cilengitide, laboratory biomarker analysis, pharmacological study
- Where
- 20 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00058123
- Testing
- poly ICLC
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oligodendroglioma, Astrocytoma
First in Patient Study for PF-06840003 in Malignant Gliomas
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
- Conditions
- Oligodendroglioma, Astrocytoma, Malignant Glioma
- Trial name
- NCT02764151
- Testing
- PF-06840003
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Pfizer
Astrocytoma, Glioma
Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine.
- Conditions
- Astrocytoma, Glioma, Oligodendroglioma
- Trial name
- NCT00360828
- Testing
- Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute